NA
APLS

Neuburgh Advisers’s Apellis Pharmaceuticals APLS Stock Holding History

Neuburgh Advisers’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$24K Buy
+1,012
New +$27.9K ﹤0.01% 877
2019
Q1 		– Sell
-1,782
Closed -$23K – 912
2018
Q4 		$23K Buy
+1,782
New +$27.3K ﹤0.01% 857

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Neuburgh Advisers's APLS Position: Q3 2019 in Review

Neuburgh Advisers opened a new position in Apellis Pharmaceuticals (APLS) in Q3 2019: 1,012 shares worth $24K. The stake represents ﹤0.01% of the portfolio and ranks #877 among its holdings. This is a return to the name: Neuburgh Advisers previously reported a position in APLS as recently as Q4 2018.

Neuburgh Advisers first reported a position in APLS in Q4 2018 and has held it in 2 quarters since. 129 funds tracked by Wall St. Rank hold APLS as of Q3 2019.

  • Neuburgh Advisers held 1,012 shares of Apellis Pharmaceuticals worth $24K as of Q3 2019.
  • Apellis Pharmaceuticals was a new Neuburgh Advisers position in Q3 2019.
  • Apellis Pharmaceuticals made up ﹤0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #877 holding.
  • Neuburgh Advisers first reported a position in Apellis Pharmaceuticals in Q4 2018 and has held it in 2 quarters since.
  • 129 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.